Literature DB >> 15772683

A prospective randomized study to optimize the dosage of trimix ingredients and compare its efficacy and safety with prostaglandin E1.

R Seyam1, K Mohamed, A Al Akhras, H Rashwan.   

Abstract

Intracavernous injection of Trimix (Tx) is indicated for patients unsuitable for prostaglandin E1 (PgE1) injection due to lack of response, pain or cost. We believe that the ideal ratio of ingredient doses in Tx is yet to be found. We postulated that increasing the doses of individual drug components in an orderly manner would convey important data on penile hemodynamic response. Such information is needed to choose an effective and less costly alternative to PgE1 with least side effects. We set out to evaluate the impact of varying the ingredient dosage on response and short-term safety of Tx compared with PgE1. We prospectively randomized 180 consecutive patients with erectile dysfunction into nine equal groups and each group received a different dose of Tx, namely phentolamine (1 mg) plus one dose of PgE1 (2.5, 5 or 10 microg) and one dose of papaverine (5, 10 or 20 mg). Each patient was injected with 20 microg PgE1 and one dose of Tx in two clinic visits 1 week apart. Following injection, duplex ultrasound of cavernous arteries and axial rigidometry were carried out. Patients ranked the quality of erection, estimated overall satisfaction and reported time to detumescence and side effects. Patients' mean age was 50.5+/-11.7 y with underlying organic condition in 91.1%. There were no significant differences between PgE1 and Tx with regard to peak cavernous artery flow, time to erection, patients' satisfaction, average axial rigidity and pain. PgE1 produced higher end diastolic velocity, shorter duration of erection and less priapism. Patients did not show a preference for either drug or any particular dosage. We conclude that even at the smallest dose of ingredients of Tx, there are no significant differences in hemodynamic effects, rigidity, pain and self-satisfaction between the two drugs. However, Tx produces a longer duration of erection and more priapism than PgE1.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15772683     DOI: 10.1038/sj.ijir.3901313

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  7 in total

1.  Current Diagnosis and Management of Erectile Dysfunction.

Authors:  Alexander W Pastuszak
Journal:  Curr Sex Health Rep       Date:  2014-09

Review 2.  The treatment of erectile dysfunction in patients with neurogenic disease.

Authors:  Anand N Shridharani; William O Brant
Journal:  Transl Androl Urol       Date:  2016-02

3.  An Empirical vs Risk-Based Approach Algorithm to Intracavernosal Injection Therapy: A Prospective Study.

Authors:  Helen Levey Bernie; Robert Segal; Brian Le; Arthur Burnett; Trinity J Bivalacqua
Journal:  Sex Med       Date:  2017-03       Impact factor: 2.491

4.  Evaluation of the sensitivity of different doses of vasoactive drugs in diagnosing erectile dysfunction in impotent patients: a prospective case-control study.

Authors:  Shady Zaki Said; Taha Abdel Nasser; Mohammad Ayad; Ahmad Tarek Motawi
Journal:  Cent European J Urol       Date:  2021-02-06

5.  Complication Rates in Patients Using Intracavernosal Injection Therapy for Erectile Dysfunction With or Without Concurrent Anticoagulant Use-A Single-Center, Retrospective Pilot Study.

Authors:  Kyle A Blum; Justin P Mehr; Travis Green; Lauren Conroy; Vanessa Marino; Daniel Kim; Kailash Panchapakesan; Liam Murphy; Sravan Panuganti; Run Wang
Journal:  Sex Med       Date:  2022-06-03       Impact factor: 2.523

Review 6.  A summary of the controversy surrounding off-label medications in men's health.

Authors:  Adam Parker; Matthew Bruha; Oluwaseun Akinola; Charles Welliver
Journal:  Transl Androl Urol       Date:  2016-04

7.  Noninvasive treatments for iatrogenic priapism: Do they really work? A prospective multicenter study.

Authors:  Mohamad Habous; Mohammed Elkhouly; Osama Abdelwahab; Mohammed Farag; Khaled Madbouly; Talal Altuwaijri; Marco Spilotros; Carlo Bettocchi; Saleh Binsaleh
Journal:  Urol Ann       Date:  2016 Apr-Jun
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.